Clinical trial
A Prospective, Single-arm, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
NCT04807166 is registered in ClinicalTrials.gov with Wenjun Cheng as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Single-arm, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
- Lead sponsor
- Wenjun Cheng
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- August 24, 2021
- Completion date
- December 31, 2027
- Enrollment
- 56 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
angiogenesis, anlotinib, antineoplastic agents, carcinoma, carcinoma, ovarian epithelial, endocrine system diseases, fallopian tube neoplasms, genital diseases, female, genital neoplasms, female, neoplasms by histologic type, neoplasms by site, neoplasms, glandular and epithelial, ovarian diseases, ovarian neoplasms, tyrosine kinase inhibitor